Congenital Factor VII Deficiency Treatment Market Size, Share & Industry Analysis, By Treatment (Recombinant factor VIIa (rFVIIa), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

The human body undertakes a series of complex mechanims in order to stop bleeding and these mechanisms include the creation of blood clot. In the creation of blood clot, requires factor VII, a type of protein. Factor VII acts by binding itself to tissue factor at the site of injury to the blood vessel in order to generate thrombin, which is critical for the formation of fibrin. Congenital factor VII deficiency refers to a disorder where there are low levels of factor VII in the blood. Moreover, the increasing awareness and R&D have also aided the expansion of congenital factor VII deficiency treatment industry. As of 2019, Novo Nordisk A/S product offering of NovoSeven (coagulation Factor VIIa, recombinant) is the only product offering approved by the FDA for the treatment of congenital factor VII deficiency.

Global congenital factor VII deficiency treatment  market growth is being driven by the increase in awareness for rare bleeding disorders and anticipated product launches for bleeding disorders. Furthermore, the rise in the efficiency of approved product offerings, leading to an increased adoption of advanced therapeutics is expected to further drive the global congenital factor VII deficiency treatment market growth during the forecast period. According to the Novo Nordisk A/S, the prevalence of congenital factor VII deficiency is estimated to affect 1 in 500,000 patients with male and female patients equally affected.

On the flip side, the extremely rare nature of the disorder and the underreporting and non-diagnosis of patients are the factors that can restrain the growth in global congenital factor VII deficiency treatment market.

Key Players Covered:

The major companies covered in the global congenital factor VII deficiency treatment  market report include Novo Nordisk A/S, Biogen, CSL, and other players.

As per the current congenital factor VII deficiency treatment market trends, recombinant factor VIIa (rFVIIa) among the treatment segment are anticipated to register a higher market share in the global congenital factor VII deficiency treatment market owing to recombinant factor VIIa (rFVIIa) being one of the most primary and critical treatment options.

Key Insights:

• Prevalence of Congenital Factor VII Deficiency, By Key Regions, 2018


• New Product Launches


• Overview of Treatment Methods for Congenital Factor VII Deficiency


• Key Industry Developments

Regional Analysis:

The global congenital factor VII deficiency treatment market has been segmented into North America, Europe, Asia Pacific, and rest of the world. The congenital factor VII deficiency treatment market is anticipated to expand in North America during the forecast years owing to the fast adoption to advanced therapeutics and increased awareness regarding rare bleeding disorders. In Europe, the prevalence of congenital factor VII deficiency is estimated to be 1 in 300,000 and increased awareness is anticipated to augment the congenital factor VII deficiency treatment market by the end of 2026.

In Asia Pacific, the evolving healthcare infrastructure, increasing disposable incomes and increasing awareness regarding bleeding disorders are anticipated to fuel the congenital factor VII deficiency treatment  market growth during the forecast period. Additionally, congenital factor VII deficiency treatment market in the rest of the world such as Latin America and the Middle East & Africa is in the nascent stage; however, unmet needs for bleeding disorders is expected to drive the market growth in this region.

Segmentation

Congenital Factor VII Deficiency Treatment Industry Developments

• As of February 2019, a clinical study comparing the pharmacokinetic of biosimilar Eptacog Alfa With Novoseven, in patients with congenital factor VII deficiency, sponsored by AryoGen Pharmed Co., was in Phase 3 of clinical trials


• In April 2015, Pfizer announced the termination of a partnership for the development of Factor VIIa product offerings